BHVN vs LLY
BHVN: Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | BHVN | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $13.85 | $1,255.40 | |
| Market cap as of 2026-08-24 | $2.1B | $1.18T | |
| P/E as of 2026-08-24 | n/a | 43.17 | |
| PEG as of 2026-08-24 | n/a | 1.48 | |
| Net margin as of 2026-08-24 | n/a | +33.5% | |
| Gross margin as of 2026-08-24 | n/a | +83.4% | |
| Operating margin as of 2026-08-24 | n/a | +42.2% | |
| ROE as of 2026-08-24 | -450.0% | +92.6% | LLY higher |
| ROA as of 2026-08-24 | -138.0% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 1.87 | 1.62 | LLY lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +49.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +31.7% | |
| Dividend yield as of 2026-08-24 | n/a | +0.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 3.09 | 0.46 | |
| 1-year return as of 2026-08-21 close | -5.7% | +76.9% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.